Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor
About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors (anti-VEGFR-TKI). Efficacy of second-line therapy is usually limited and prognostic and predi...
Gespeichert in:
| Veröffentlicht in: | Acta Oncologica 2016-03, Vol.55 (3), p.329-40 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 40 |
|---|---|
| container_issue | 3 |
| container_start_page | 329 |
| container_title | Acta Oncologica |
| container_volume | 55 |
| creator | Sacré, Anne Barthélémy, Philippe Korenbaum, Clement Burgy, Mickael Wolter, Pascal Dumez, Herlinde Lerut, Evelyne Loyson, Tine Joniau, Steven Oyen, Raymond Debruyne, Philip R Schöffski, Patrick Beuselinck, Benoit |
| description | About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors (anti-VEGFR-TKI). Efficacy of second-line therapy is usually limited and prognostic and predictive factors at the start of second-line therapy are lacking. To identify the subgroup of patients that will benefit from such treatment remains a challenge. |
| format | Article |
| fullrecord | <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_123456789_512812</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>123456789_512812</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_123456789_5128123</originalsourceid><addsrcrecordid>eNqNTkFOw0AM3ANIlMIffOOAIqVJ04YzAnHkwIFb5G6cZOl2N7KdQv_Hw9igPqDSSJ6R7Zm5Mou8qNfZqt583phbka88z4tyWy3M7zvHPkRRZ6FDq5EFXAAhG0ObeRcIFLknpRZ0IMbxBF1kOJCiKM5v1hNyZsl7YAro4Z9aZOtCPCBgp8QwphwmERcDJOAMddkRxU4eGSi0MQV4lwx6jt86nPskU0vjTPTEUeZGexdQKPUc3M6lzZ257tAL3Z_n0jy8vnw8v2X7ydN0pNC0MqKlZlWU62qzrZ-aalXUSS3N42WXjf5oebnvH8fVejY</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor</title><source>Lirias (KU Leuven Association)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Taylor & Francis Journals Complete</source><source>Alma/SFX Local Collection</source><creator>Sacré, Anne ; Barthélémy, Philippe ; Korenbaum, Clement ; Burgy, Mickael ; Wolter, Pascal ; Dumez, Herlinde ; Lerut, Evelyne ; Loyson, Tine ; Joniau, Steven ; Oyen, Raymond ; Debruyne, Philip R ; Schöffski, Patrick ; Beuselinck, Benoit</creator><creatorcontrib>Sacré, Anne ; Barthélémy, Philippe ; Korenbaum, Clement ; Burgy, Mickael ; Wolter, Pascal ; Dumez, Herlinde ; Lerut, Evelyne ; Loyson, Tine ; Joniau, Steven ; Oyen, Raymond ; Debruyne, Philip R ; Schöffski, Patrick ; Beuselinck, Benoit</creatorcontrib><description>About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors (anti-VEGFR-TKI). Efficacy of second-line therapy is usually limited and prognostic and predictive factors at the start of second-line therapy are lacking. To identify the subgroup of patients that will benefit from such treatment remains a challenge.</description><identifier>ISSN: 0284-186X</identifier><language>eng</language><publisher>Acta Oncologica</publisher><ispartof>Acta Oncologica, 2016-03, Vol.55 (3), p.329-40</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,780,784,27859</link.rule.ids></links><search><creatorcontrib>Sacré, Anne</creatorcontrib><creatorcontrib>Barthélémy, Philippe</creatorcontrib><creatorcontrib>Korenbaum, Clement</creatorcontrib><creatorcontrib>Burgy, Mickael</creatorcontrib><creatorcontrib>Wolter, Pascal</creatorcontrib><creatorcontrib>Dumez, Herlinde</creatorcontrib><creatorcontrib>Lerut, Evelyne</creatorcontrib><creatorcontrib>Loyson, Tine</creatorcontrib><creatorcontrib>Joniau, Steven</creatorcontrib><creatorcontrib>Oyen, Raymond</creatorcontrib><creatorcontrib>Debruyne, Philip R</creatorcontrib><creatorcontrib>Schöffski, Patrick</creatorcontrib><creatorcontrib>Beuselinck, Benoit</creatorcontrib><title>Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor</title><title>Acta Oncologica</title><description>About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors (anti-VEGFR-TKI). Efficacy of second-line therapy is usually limited and prognostic and predictive factors at the start of second-line therapy are lacking. To identify the subgroup of patients that will benefit from such treatment remains a challenge.</description><issn>0284-186X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqNTkFOw0AM3ANIlMIffOOAIqVJ04YzAnHkwIFb5G6cZOl2N7KdQv_Hw9igPqDSSJ6R7Zm5Mou8qNfZqt583phbka88z4tyWy3M7zvHPkRRZ6FDq5EFXAAhG0ObeRcIFLknpRZ0IMbxBF1kOJCiKM5v1hNyZsl7YAro4Z9aZOtCPCBgp8QwphwmERcDJOAMddkRxU4eGSi0MQV4lwx6jt86nPskU0vjTPTEUeZGexdQKPUc3M6lzZ257tAL3Z_n0jy8vnw8v2X7ydN0pNC0MqKlZlWU62qzrZ-aalXUSS3N42WXjf5oebnvH8fVejY</recordid><startdate>201603</startdate><enddate>201603</enddate><creator>Sacré, Anne</creator><creator>Barthélémy, Philippe</creator><creator>Korenbaum, Clement</creator><creator>Burgy, Mickael</creator><creator>Wolter, Pascal</creator><creator>Dumez, Herlinde</creator><creator>Lerut, Evelyne</creator><creator>Loyson, Tine</creator><creator>Joniau, Steven</creator><creator>Oyen, Raymond</creator><creator>Debruyne, Philip R</creator><creator>Schöffski, Patrick</creator><creator>Beuselinck, Benoit</creator><general>Acta Oncologica</general><scope>FZOIL</scope></search><sort><creationdate>201603</creationdate><title>Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor</title><author>Sacré, Anne ; Barthélémy, Philippe ; Korenbaum, Clement ; Burgy, Mickael ; Wolter, Pascal ; Dumez, Herlinde ; Lerut, Evelyne ; Loyson, Tine ; Joniau, Steven ; Oyen, Raymond ; Debruyne, Philip R ; Schöffski, Patrick ; Beuselinck, Benoit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_123456789_5128123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sacré, Anne</creatorcontrib><creatorcontrib>Barthélémy, Philippe</creatorcontrib><creatorcontrib>Korenbaum, Clement</creatorcontrib><creatorcontrib>Burgy, Mickael</creatorcontrib><creatorcontrib>Wolter, Pascal</creatorcontrib><creatorcontrib>Dumez, Herlinde</creatorcontrib><creatorcontrib>Lerut, Evelyne</creatorcontrib><creatorcontrib>Loyson, Tine</creatorcontrib><creatorcontrib>Joniau, Steven</creatorcontrib><creatorcontrib>Oyen, Raymond</creatorcontrib><creatorcontrib>Debruyne, Philip R</creatorcontrib><creatorcontrib>Schöffski, Patrick</creatorcontrib><creatorcontrib>Beuselinck, Benoit</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>Acta Oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sacré, Anne</au><au>Barthélémy, Philippe</au><au>Korenbaum, Clement</au><au>Burgy, Mickael</au><au>Wolter, Pascal</au><au>Dumez, Herlinde</au><au>Lerut, Evelyne</au><au>Loyson, Tine</au><au>Joniau, Steven</au><au>Oyen, Raymond</au><au>Debruyne, Philip R</au><au>Schöffski, Patrick</au><au>Beuselinck, Benoit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor</atitle><jtitle>Acta Oncologica</jtitle><date>2016-03</date><risdate>2016</risdate><volume>55</volume><issue>3</issue><spage>329</spage><epage>40</epage><pages>329-40</pages><issn>0284-186X</issn><abstract>About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors (anti-VEGFR-TKI). Efficacy of second-line therapy is usually limited and prognostic and predictive factors at the start of second-line therapy are lacking. To identify the subgroup of patients that will benefit from such treatment remains a challenge.</abstract><pub>Acta Oncologica</pub><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0284-186X |
| ispartof | Acta Oncologica, 2016-03, Vol.55 (3), p.329-40 |
| issn | 0284-186X |
| language | eng |
| recordid | cdi_kuleuven_dspace_123456789_512812 |
| source | Lirias (KU Leuven Association); EZB-FREE-00999 freely available EZB journals; Taylor & Francis Journals Complete; Alma/SFX Local Collection |
| title | Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T12%3A56%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20factors%20in%20second-line%20targeted%20therapy%20for%20metastatic%20clear-cell%20renal%20cell%20carcinoma%20after%20progression%20on%20an%20anti-vascular%20endothelial%20growth%20factor%20receptor%20tyrosine%20kinase%20inhibitor&rft.jtitle=Acta%20Oncologica&rft.au=Sacr%C3%A9,%20Anne&rft.date=2016-03&rft.volume=55&rft.issue=3&rft.spage=329&rft.epage=40&rft.pages=329-40&rft.issn=0284-186X&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E123456789_512812%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |